Company intelligence / Profile preview

Visiopharm

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Visiopharm’s AI-driven precision pathology software is commercially available worldwide. Its CE-IVD certified diagnostic algorithms are used in clinical practice to support decision-making in cancer diagnostics. The platform has been featured in over 3,300 scientific publications and supports both research and clinical applications with validated performance.

Modalities: Digital Pathology SoftwareImage Analysis Platforms
Industry: Pathology

Partnerships

Agilent Technologies Inc.Deep Bio Inc.PhilipsSectraHamamatsu Photonics

Beyond the preview

Go deeper on Visiopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visiopharm.

Explore the full profile